Antihypertensive Drugs Market Projected to Expand at a CAGR of 3.0% from 2022 to 2030, Data by Contrive Datum Insights
January 16, 2023 08:58 ET
|
Contrive Datum Insights Pvt Ltd
Farmington, Jan. 16, 2023 (GLOBE NEWSWIRE) -- The Antihypertensive Drugs Market is estimated to reach a valuation of USD 30.2 Billion by 2022, growing at 3.0% CAGR during the assessment period...
Immuno-oncology Global Market Report 2022: Approval of Novel Therapies Boosts Sector Growth
November 30, 2022 05:48 ET
|
Research and Markets
Dublin, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The "Immuno-oncology Market Size, Share, Trends, Analysis and Forecast by Region, Segment, Type (Checkpoint Modulators, Cancer Vaccines) and End-User...
Global Bacteriophage Therapy Market Report 2022: Minimal Drug Toxicity, Self-Replication and Less Side Effects Among Benefits Fueling Adoption
November 28, 2022 08:43 ET
|
Research and Markets
Dublin, Nov. 28, 2022 (GLOBE NEWSWIRE) -- The "Bacteriophage Therapy Market: Distribution by Therapeutic Area, Route of Administration, and Geography: Industry Trends and Global Forecasts,...
Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic Therapy
September 08, 2022 16:05 ET
|
Alpha Tau Medical Ltd.
– Study on combination with anti-PD1 therapy published by International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, the official journal of the American...
Pet Cancer Therapeutics Market to hit USD 760 million by 2030, says Global Market Insights Inc.
August 16, 2022 03:15 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Aug. 16, 2022 (GLOBE NEWSWIRE) -- The pet cancer therapeutics market value is anticipated to be valued over USD 760 million by 2030. Rising awareness pertaining to pet diseases...
Immuno-Oncology Drug Development Analytical Tool 2022: 1260 Companies/Partners Who are Developing 3,896 I-O Drugs Where of 2,948 are in Active Development in Cancer Across 629 Different Targets
May 26, 2022 06:28 ET
|
Research and Markets
Dublin, May 26, 2022 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Drug Development: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. Immuno-Oncology Drug Development:...
Next Generation Complement Therapeutics Markets, 2035
April 04, 2022 10:08 ET
|
Research and Markets
Dublin, April 04, 2022 (GLOBE NEWSWIRE) -- The "Next Generation Complement Therapeutics Market: Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of...
Neoantigens Market Size ($10,54,783.54 Thousand by 2028) Growth Forecast at 31.2% CAGR During 2023 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
October 07, 2021 10:16 ET
|
The Insight Partners
New York, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Neoantigens Market: Key InsightsAccording to our new research study on “Neoantigens Market to 2028 – Global Analysis and Forecast – by Treatment and...
GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients
August 24, 2020 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Aug. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases...
AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
August 11, 2020 16:01 ET
|
AzurRx BioPharma, Inc.
Data from first five patients demonstrate positive results with primary efficacy and secondary safety endpoints achievedClinically meaningful improvement (>80%) in coefficient of fat absorption...